Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Filgrastim (Filgrastim/SBS) 300 mcg versus Filgrastim (Filgrastim/CIM) 300 mcg in healthy Thai volunteers
TCTR20180321003Phase 1Completed
- Sponsor
- Siam Bioscience Co., Ltd.
- Start
- Jun 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgrastim (2 arms), sponsored by Siam Bioscience Co., Ltd. Primary endpoint: Pharmacokinetic bioequivalence. Started Jun 2018; status: completed.
02
Drugs
filgrastim
Beyond the preview
Go deeper on TCTR20180321003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180321003.